Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 3/20 | 0.57 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28541193 | 0.82 | LTB4R (0.44) | LTB4RLTB4R2PPARDPPARA | |
| SCHEMBL11097326 | 0.82 | CXCL8 (0.79) | CXCL8CHRM1CAMK2AL3MBTL1AKR1B1 | |
| SCHEMBL9447429 | 0.80 | CHRM1 (0.52) | CXCL8LTB4RLTB4R2CHRM1PPARG | |
| SCHEMBL982656 | 0.78 | LTB4R (0.44) | LTB4RLTB4R2 | |
| SCHEMBL1834651 | 0.78 | LTB4R (0.50) | LTB4RLTB4R2PPARGPPARDPPARA | |
| SCHEMBL4032382 | 0.77 | AKR1B1 (0.57) | CXCL8PPARGPPARAAKR1B1TDP1 | |
| SCHEMBL28668247 | 0.77 | LTB4R (0.49) | LTB4RLTB4R2PPARGPPARDPPARA | |
| SCHEMBL1253400 | 0.76 | CXCL8 (0.66) | CXCL8CHRM1CAMK2AL3MBTL1AKR1B1 | |
| SCHEMBL29580839 | 0.76 | LTB4R (0.48) | LTB4RLTB4R2PPARGPPARDPPARA | |
| SCHEMBL1835083 | 0.76 | LTB4R (0.48) | LTB4RLTB4R2PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020988-A3 | METHOD AND APPARATUS TO ENABLE SWITCHING BETWEEN TWO CARRIERS IN A CELLULAR COMMUNICATION NETWORK | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-05-10 | — | — | WO | disclosed |
| US-20120094913-A1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110046188-A1 | COMPOSITIONS COMPRISING NOVEL PPAR LIGANDS AND ANTI-HYPERLIPEMIC AGENTS | BETHESDA PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7867991-B2 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | BETHESDA PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1886683-B1 | Novel PPAR ligands that do not cause fluid retention edema or congestive heart failure | BETHESDA PHARMACEUTICALS INC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7812046-B2 | PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080242712-A1 | Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1886683-A1 | Novel PPAR ligands that do not cause fluid retention edema or congestive heart failure | Bethesda Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1878427-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | Bethesda Pharmaceuticals, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20080009536-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1839660-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | Bethesda Pharmaceuticals, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070203213-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070185070-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7232828-B2 | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1536785-B1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS INC (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070054949-A1 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | BETHESDA PHARMACEUTICALS, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1536785-A4 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1536785-A2 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | Bethesda Pharmaceuticals, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040127443-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| WO-2004014308-A2 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242712-A1 | Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | CXCL8 1034/4885LTB4R 272/4885LTB4R2 199/4885 |
| US-20080009536-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | CXCL8 1025/4885LTB4R 318/4885LTB4R2 227/4885 |
| US-20110046188-A1 | COMPOSITIONS COMPRISING NOVEL PPAR LIGANDS AND ANTI-HYPERLIPEMIC AGENTS | HDLBP, PPARA, PPARG | CXCL8 4043/4885LTB4R 732/4885LTB4R2 770/4885 |
| US-20070185070-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | CXCL8 1025/4885LTB4R 318/4885LTB4R2 227/4885 |
| US-20120094913-A1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | PPARA, PPARG, PPARD | CXCL8 1025/4885LTB4R 318/4885LTB4R2 227/4885 |
| US-20040127443-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | CXCL8 1025/4885LTB4R 318/4885LTB4R2 227/4885 |
| US-20070054949-A1 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | HDLBP, PPARA, PPARG | CXCL8 4043/4885LTB4R 732/4885LTB4R2 770/4885 |
| US-20070203213-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | CXCL8 1025/4885LTB4R 318/4885LTB4R2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.